Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
NEWTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the […]